Vyome Holdings, Inc HIND
Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the "Company") completed the merger pursuant to the Agreement and Plan
of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Company, Raider Lifesciences Inc.,
a wholly owned subsidiary of the Company ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome"). Pursuant to the
Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the "Merger").
Last close
1.79
2026-10-23
Market cap
$12.6M
2026-06-30 share count
52-week range
1.75 - 6.56
Valuation FY2025 figures against the last close
P/S39.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-4.86
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $319.7K | $256.9K | $8.7M | $11.2M | $13.6M | $11.3M | $3.3M | $9.1M | $9.9M | $3.4M |
| Cost of revenue | $100.9K | $62.0K | $3.1M | $4.4M | $5.3M | $5.0M | $3.0M | $5.4M | $4.8M | $2.8M |
| Gross profit | $218.8K | $195.0K | $5.5M | $6.8M | $8.3M | $6.3M | $331.0K | $3.7M | $5.1M | $584.0K |
| R&D | $588.3K | $285.4K | $2.3M | $2.5M | $2.4M | $3.5M | $6.9M | $10.7M | $10.6M | $9.9M |
| SG&A | $2.4M | $898.6K | $10.3M | $14.1M | $8.9M | $4.7M | $16.7M | $29.9M | $28.8M | $10.2M |
| Total operating expenses | $10.7M | $1.2M | $20.9M | $53.2M | $66.2M | $18.7M | $23.6M | $40.6M | $39.5M | $20.1M |
| Operating income | -$10.5M | -$1.0M | -$15.4M | -$46.4M | -$57.9M | -$12.5M | -$23.2M | -$37.0M | -$34.4M | -$19.5M |
| Interest expense | $146.6K | $206.0K | — | — | — | — | — | — | — | — |
| Pre-tax income | — | -$7.1M | -$11.3M | -$46.6M | -$63.4M | -$21.8M | -$23.7M | -$37.4M | -$34.8M | -$20.5M |
| Income tax | — | $39.0K | $52.0K | $380.0K | $274.0K | $181.0K | $14.0K | $11.0K | $10.0K | $2.0K |
| Net income | -$10.3M | -$1.4M | -$11.4M | -$46.2M | -$63.1M | -$21.6M | -$23.7M | -$37.4M | -$34.8M | -$20.5M |
| EPS, basic | -4.86 | -6,001.39 | -110.87 | -108.90 | -288.97 | -5.54 | — | — | — | — |
| EPS, diluted | -4.86 | -6,001.39 | -110.87 | -108.90 | -288.97 | -5.54 | -5.03 | -19.64 | -2.08 | -4.85 |
| Shares, diluted (wtd. avg.) | 2.2M | 241 | 102,707 | 424,390 | 218,522 | 3.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.0M | $101.9K | $16.6K | $4.0M | $22.8M | $3.0M | $3.0M | $21.2M | $21.1M | $73.0M |
| Short-term investments | — | — | — | — | — | — | $0 | $2.5M | $23.3M | $2.5M |
| Receivables | $325 | $2.3K | $1.7M | — | — | — | $285.0K | $870.0K | $4.2M | $0 |
| Inventory | — | $2.5M | $3.7M | $3.6M | $3.0M | $2.2M | $1.9M | $1.6M | $1.4M | $827.0K |
| Total current assets | $5.4M | $302.0K | $10.3M | $9.9M | $65.3M | $8.9M | $18.2M | $28.6M | $51.8M | $78.1M |
| Property, plant and equipment | $46.4K | $59.2K | $60.0K | $698.0K | $1.5M | $584.0K | $1.1M | $1.7M | $1.3M | $717.0K |
| Goodwill | — | — | — | — | $23.5M | — | — | — | — | — |
| Other intangibles | $314.2K | $314.2K | — | $260.0K | $13.9M | $12.9M | — | — | — | — |
| Total assets | $6.5M | $1.4M | $10.7M | $11.1M | $120.0M | $37.1M | $20.4M | $30.4M | $53.1M | $78.8M |
| Accounts payable | $647.5K | $501.9K | $1.7M | $1.9M | $3.5M | $3.7M | $648.0K | $1.2M | $1.3M | $595.0K |
| Short-term debt | — | $811.0K | — | — | — | $3.6M | $0 | $9.9M | $2.0M | $0 |
| Total current liabilities | $2.7M | $5.7M | $3.8M | $7.5M | $7.5M | $11.6M | $4.0M | $17.2M | $10.0M | $4.6M |
| Long-term debt | — | — | — | — | — | $9.2M | — | $0 | $8.0M | $9.9M |
| Total liabilities | $2.7M | $5.8M | $4.0M | $7.5M | $8.2M | $22.6M | $4.5M | $17.3M | $18.0M | $14.5M |
| Retained earnings | -$87.6M | -$55.4M | -$635.6M | -$624.2M | -$523.6M | -$514.8M | -$172.4M | -$148.8M | -$111.4M | -$76.6M |
| Total equity | $3.8M | -$4.4M | -$6.2M | $3.7M | $44.3M | $14.5M | $24.1M | $13.1M | $35.1M | $64.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.7M | -$614.1K | -$17.0M | -$21.9M | -$15.4M | -$8.6M | -$22.9M | -$29.4M | -$30.6M | -$19.4M |
| Depreciation and amortisation | — | $22.0K | $121.0K | $330.0K | $232.0K | $15.0K | $400.0K | — | — | — |
| Stock-based compensation | $577.1K | $184.0K | $766.0K | $2.1M | $12.2M | $1.3M | $3.0M | $4.7M | $3.2M | $563.0K |
| Capital expenditure | — | — | $43.0K | $131.0K | $352.0K | $390.0K | $194.0K | $1.3M | $1.0M | $352.0K |
| Investing cash flow | — | $315 | -$10.0K | -$92.0K | $1.9M | -$2.4M | $2.4M | $19.5M | -$21.9M | $6.2M |
| Financing cash flow | $8.7M | $698.0K | $17.6M | $3.1M | $33.3M | $11.1M | $13.4M | $10.0M | $613.0K | $82.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-029500.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $9.9M | $9.1M | $3.3M | $11.3M | $13.6M | $11.2M | $8.7M | $256.9K | $319.7K |
| Gross profit | $584.0K | $5.1M | $3.7M | $331.0K | $6.3M | $8.3M | $6.8M | $5.5M | $195.0K | $218.8K |
| Net income | -$20.5M | -$34.8M | -$37.4M | -$23.7M | -$21.6M | -$63.1M | -$46.2M | -$11.4M | -$1.4M | -$10.3M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Results announced Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |